Trishula Therapeutics
Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing transformational cancer medicines, notably TTX-030, a first-in-class anti-CD39 antibody. The company focuses on targeting mechanisms of immune evasion in the tumor microenvironment and collaborates with AbbVie in its development efforts.
Industries
Nr. of Employees
small (1-50)
Trishula Therapeutics
2268 Westborough Blvd Suite 302 #263 South San Francisco, CA 94080
Patents
Products
Clinical‑stage anti‑CD39 monoclonal antibody (clinical immunotherapy)
A clinical-stage monoclonal antibody targeting CD39 designed to inhibit the conversion of extracellular ATP to AMP in the tumor microenvironment, with the intent to reduce adenosine-mediated immunosuppression and support anti-tumor immune responses. Evaluated as monotherapy and in combination with anti-PD-1 immunotherapy and standard chemotherapy in multiple solid tumor studies (Phase 1/1b and Phase 2).
Clinical‑stage anti‑CD39 monoclonal antibody (clinical immunotherapy)
A clinical-stage monoclonal antibody targeting CD39 designed to inhibit the conversion of extracellular ATP to AMP in the tumor microenvironment, with the intent to reduce adenosine-mediated immunosuppression and support anti-tumor immune responses. Evaluated as monotherapy and in combination with anti-PD-1 immunotherapy and standard chemotherapy in multiple solid tumor studies (Phase 1/1b and Phase 2).
Services
End-to-end management of early- and mid-stage oncology clinical trials including protocol development, operational execution, safety monitoring and data reporting.
Strategy and execution for process development, clinical manufacturing, technology transfer and coordination with external contract manufacturers for antibody programs.
Cross-functional program management and alliance oversight for collaborative development programs with external partners.
End-to-end management of early- and mid-stage oncology clinical trials including protocol development, operational execution, safety monitoring and data reporting.
Strategy and execution for process development, clinical manufacturing, technology transfer and coordination with external contract manufacturers for antibody programs.
Cross-functional program management and alliance oversight for collaborative development programs with external partners.
Expertise Areas
- Clinical trial management
- Immuno-oncology drug development
- Biomarker-driven clinical development
- Translational research (tumor microenvironment and ATP–adenosine pathway)
Key Technologies
- Monoclonal antibody therapeutics
- Targeting ATP–adenosine pathway (CD39 inhibition)
- Biomarker-driven patient selection (tumor HLA-DQ expression)
- Combination chemoimmunotherapy regimens
News & Updates
Final results from a Phase 1 trial of TTX-030 in patients with first-line metastatic pancreatic cancer, presented at ESMO Congress 2024, showing promising median overall survival and benefit in high tumor HLA-DQ biomarker expression.
Announcement of a randomized Phase 2 trial evaluating TTX-030 in combination with chemotherapy, with or without budigalimab, for metastatic pancreatic ductal adenocarcinoma patients.
Preliminary results from a Phase 1 trial showing encouraging signs of anti-tumor activity and safety profile in gastric and gastroesophageal junction cancer.
Details of an oral presentation at AACR 2022 on the safety and efficacy of TTX-030 in combination with chemoimmunotherapy for gastric/GEJ cancer.
Announcement of Anil Singhal's appointment as CEO of Trishula, emphasizing his leadership in advancing TTX-030.
Announcement of the company's launch and focus on TTX-030 development in collaboration with AbbVie.
Final results from a Phase 1 trial of TTX-030 in patients with first-line metastatic pancreatic cancer, presented at ESMO Congress 2024, showing promising median overall survival and benefit in high tumor HLA-DQ biomarker expression.
Announcement of a randomized Phase 2 trial evaluating TTX-030 in combination with chemotherapy, with or without budigalimab, for metastatic pancreatic ductal adenocarcinoma patients.
Preliminary results from a Phase 1 trial showing encouraging signs of anti-tumor activity and safety profile in gastric and gastroesophageal junction cancer.
Details of an oral presentation at AACR 2022 on the safety and efficacy of TTX-030 in combination with chemoimmunotherapy for gastric/GEJ cancer.
Announcement of Anil Singhal's appointment as CEO of Trishula, emphasizing his leadership in advancing TTX-030.
Announcement of the company's launch and focus on TTX-030 development in collaboration with AbbVie.